Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06083766 · ClinicalTrials.gov registry record
Metabolic and Physiologic Responses to Hormone Therapy in Transgender and Gender Diverse People
A clinical trial of Effects of GAHT, on Skeletal Muscle in TGD, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT06083766: Recruiting study of Effects of GAHT, on Skeletal Muscle in TGD, sponsored by Mayo Clinic.
NCT06083766 is a study of Effects of GAHT, on Skeletal Muscle in TGD that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06083766, a study of Effects of GAHT, on Skeletal Muscle in TGD, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this research is to determine how gender affirming hormone therapy affects muscle physiology.
Primary Outcome
To identify the impact of gender-affirming hormone therapy (GAHT) on skeletal muscle mitochondrial metabolism in transgender and gender diverse individuals.
Conditions Studied
Interventions
- BEHAVIORAL hormone therapy
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-04 |
| Est. Completion | 2026-07 |
What NCT06083766 shows while recruiting
NCT06083766 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 1 condition, with Effects of GAHT, on Skeletal Muscle in TGD appearing as the primary indexed condition, and to 1 intervention - of which hormone therapy is the first listed.
NCT06083766 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06083766 about?
NCT06083766 is a clinical study titled "Metabolic and Physiologic Responses to Hormone Therapy in Transgender and Gender Diverse People". The primary purpose of this research is to determine how gender affirming hormone therapy affects muscle physiology.
What is the current status of trial NCT06083766?
This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2024-01-04. Estimated completion is 2026-07.
What conditions does trial NCT06083766 study?
This clinical trial studies the following conditions: Effects of GAHT, on Skeletal Muscle in TGD.
What interventions are being tested in trial NCT06083766?
The interventions under investigation include: hormone therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT06083766?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06083766 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI